Furoscix Generic Name & Formulations
Carton—1 (prefilled cartridge + On-body Infusor)
Mechanism of Action
Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle.
Congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure.
Limitations of Use
Not for emergency situations or acute pulmonary edema.
Furoscix Dosage and Administration
See full labeling. Rotate inj sites. Using On-body Infusor to deliver 30mg over first hour followed by 12.5mg/hr for the subsequent 4hrs. Replace with oral diuretics as soon as practical.
Anuria. Hepatic cirrhosis. Ascites. Hypersensitivity to medical adhesives.
Furoscix Boxed Warnings
Fluid, electrolyte, metabolic abnormalities (esp. with higher doses, inadequate oral electrolyte intake, and elderly). Monitor serum electrolytes, CO2, BUN, creatinine, glucose, uric acid frequently. Discontinue if increasing azotemia and oliguria occur while treating severe progressive renal disease. Acute urinary retention; monitor carefully. Elderly. Pregnancy. Nursing mothers.
91–99% plasma protein bound.
Renal. Half-life: ~2hrs.
May increase risk of ototoxicity with concomitant aminoglycosides (avoid unless life-threatening), ethacrynic acid (avoid), cisplatin. Ototoxicity, nephrotoxicity with cisplatin and nephrotoxic drugs (give lower doses of furosemide with positive fluid balance); monitor renal function. Concomitant salicylates; montor for toxicity. Potentiates lithium (avoid), succinylcholine. Concomitant ACEIs, ARBs, other antihypertensives, (peripheral) adrenergic blockers, cephalosporin, phenytoin, indomethacin: monitor and interrupt or adjust dose as needed. Antagonized by, and potentiates, methotrexate and others that undergo renal tubular secretion. Concomitant norepinephrine; monitor BP. Concomitant chloral hydrate: not recommended. Concomitant cyclosporine: monitor serum urate levels. High doses (>80mg) may affect thyroid hormone levels.
Furoscix Adverse Reactions
Erythema, bruising, edema, infusion site pain; lab abnormalities, renal impairment, ototoxicity.
Furoscix Clinical Trials
Furoscix Patient Counseling